Market ends in positive!!
The markets ended in green with decent gains after swinging between the positive and the negative territory during the day.Real estate stocks rebounded after their severe pounding, which had eroded 25 - 50% value of such stocks.
The 30-share BSE Sensex settled 80.35 points higher, at 12,982.98.The S&P CNX Nifty gained 35.95 points to finish the day at 3,770.65.FMCG major HLL was the top loser, down 2.68% to Rs 180.05.Bharti Airtel (down 1.14% to Rs 761), Infosys (down 0.67% to Rs 2101) and REL (down 1.82% to Rs 465.50) were the other losers.
Ranbaxy dropped 0.96% to Rs 320.70, after Pfizer, the world's biggest drugmaker, sued Ranbaxy to block a generic form of the cholesterol and blood pressure medicine Caduet. Ranbaxy seeks US FDA approval to sell a low-cost version of Caduet, which combines Pfizer's blood pressure drug Norvasc with the cholesterol treatment Lipitor, the world's best-selling medicine.
Grasim was the top gainer, up 2.26% to Rs 2059.85.Software stocks rose on renewed buying. Satyam Computers (up 1.67% to Rs 449.80), Wipro (up 1.47% to Rs 581.45) and TCS (up 2.10% to Rs 1264) edged ahead.
The 30-share BSE Sensex settled 80.35 points higher, at 12,982.98.The S&P CNX Nifty gained 35.95 points to finish the day at 3,770.65.FMCG major HLL was the top loser, down 2.68% to Rs 180.05.Bharti Airtel (down 1.14% to Rs 761), Infosys (down 0.67% to Rs 2101) and REL (down 1.82% to Rs 465.50) were the other losers.
Ranbaxy dropped 0.96% to Rs 320.70, after Pfizer, the world's biggest drugmaker, sued Ranbaxy to block a generic form of the cholesterol and blood pressure medicine Caduet. Ranbaxy seeks US FDA approval to sell a low-cost version of Caduet, which combines Pfizer's blood pressure drug Norvasc with the cholesterol treatment Lipitor, the world's best-selling medicine.
Grasim was the top gainer, up 2.26% to Rs 2059.85.Software stocks rose on renewed buying. Satyam Computers (up 1.67% to Rs 449.80), Wipro (up 1.47% to Rs 581.45) and TCS (up 2.10% to Rs 1264) edged ahead.
Labels: Nifty.Sensex
0 Comments:
Post a Comment
<< Home